Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir with Ribavirin in Adults with Chronic HCV Genotype 4 Infection in Egypt (AGATE-II) [Abstract 708]
Journal
66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 13-17, 2015
